Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG6050 in Advanced Non-small Cell Lung Cancer
NCT05788926Phase 1Terminated
- Sponsor
- Transgene SA
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TG6050 in non-small cell lung cancer (NSCLC), sponsored by Transgene SA. Primary endpoint: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0) up to 5 years. Started Apr 2023; status: terminated.
02
Drugs
TG6050
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05788926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788926.